SNDX Syndax Pharmaceuticals Inc
Pharmaceutical Preparations · Nasdaq · SEC CIK 1395937 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY159.7%
TTM net income YoY32.8%
TTM EPS YoY34.2%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-61.7%
Net margin-72.3%
FCF margin—
EBITDA margin-55.5%
Returns
ROE-426.4%
ROA-33.7%
ROIC (approx.)—
Asset turnover0.47x
Leverage & solvency
Liabilities / assets102.5%
Debt / equity—
Current ratio4.69x
Interest coverage-44,660.00x
Cash quality & payout
Operating cash flow / net income0.85x
Accruals ratio-5.2%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $83.30M | $72.79M | $64.86M | $68.73M | $45.87M | $37.96M | $20.04M | $7.68M |
| R&D expense | $67.48M | $68.04M | $58.84M | $78.64M | $56.28M | $62.23M | $61.64M | $65.53M |
| SG&A expense | $43.72M | $41.54M | $37.59M | $49.93M | $44.92M | $43.80M | $41.03M | $37.69M |
| Operating income | -$41.90M | -$39.99M | -$34.20M | -$62.55M | -$57.43M | -$69.35M | -$83.76M | -$96.36M |
| Interest expense | $2,000 | $2,000 | $0 | $0 | $0 | $4,000 | $2,000 | $4.81M |
| Income tax | $0 | $0 | $0 | $433,000 | $0 | $0 | $0 | — |
| Net income | -$49.43M | -$49.36M | -$42.67M | -$68.01M | -$60.72M | -$71.85M | -$84.85M | -$94.17M |
| EBITDA | -$35.90M | -$34.99M | -$30.20M | -$59.55M | -$54.43M | -$69.35M | -$83.76M | — |
| EPS (basic) | -0.55 | -0.55 | -0.48 | — | -0.70 | -0.83 | -0.98 | — |
| EPS (diluted) | -0.55 | -0.55 | -0.48 | — | -0.70 | -0.83 | -0.98 | — |
| Weighted avg. shares (diluted) | 89.79M | 88.99M | 88.26M | — | 86.62M | 86.34M | 86.17M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $135.94M | $336.48M | $130.89M | $134.93M | $116.81M | $108.64M | $153.99M | $154.08M |
| Short-term investments | $291.16M | $211.38M | $221.17M | $259.14M | $319.17M | $346.60M | $358.20M | $418.80M |
| Receivables | — | — | — | $38.00M | — | — | — | $7.60M |
| Inventory | $39.38M | $33.16M | $34.95M | $32.75M | $25.00M | $17.70M | $4.66M | $366,000 |
| Current assets | $567.44M | $675.04M | $471.18M | $528.08M | $529.83M | $531.68M | $548.75M | $603.06M |
| PP&E, net | $206,000 | $212,000 | $177,000 | $181,000 | $128,000 | $0 | $0 | $0 |
| Total assets | $692.67M | $703.65M | $472.67M | $529.71M | $551.79M | $596.15M | $640.71M | $724.82M |
| Current liabilities | $120.96M | $99.68M | $86.17M | $120.12M | $114.19M | $112.99M | $94.55M | $103.55M |
| Short-term debt | $344.10M | $344.03M | $343.96M | $343.91M | $343.91M | $343.85M | $343.79M | $343.68M |
| Total liabilities | $709.85M | $688.55M | $431.05M | $465.08M | $436.36M | $438.73M | $425.65M | $436.69M |
| Shareholders' equity | -$17.18M | $15.10M | $41.62M | $64.63M | $115.43M | $157.42M | $215.06M | $288.12M |
| Shares outstanding | 89.99M | 89.15M | 88.54M | 87.41M | 86.91M | 86.06M | 86.05M | 85.69M |
| Cash flow statement | ||||||||
| Operating cash flow | -$27.25M | -$30.27M | -$50.34M | -$69.49M | -$70.53M | -$87.80M | -$95.16M | -$57.39M |
| Investing cash flow | -$176.47M | -$16.91M | $38.39M | $81.58M | $72.43M | $41.89M | $94.14M | -$268.97M |
| Financing cash flow | $3.19M | $252.77M | $7.92M | $5.92M | $6.28M | $551,000 | $930,000 | $347.43M |
| Depreciation & amortization | $6.00M | $5.00M | $4.00M | $3.00M | $3.00M | $0 | $0 | — |
| Stock-based compensation | $15.29M | $14.01M | $12.05M | $11.25M | $12.08M | $13.79M | $10.38M | $12.30M |
Free plan shows the latest 8 periods; Pro shows all 47 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.